|
Cancer History
and Other Personal Factors Affect Quality of Life in Patients
with Hepatitis C
Although patients with chronic
hepatitis C (CHC) have been found to have reduced quality
of life, little is known about how other characteristics
affect their quality of life. The purpose of this study was
to investigate the effect of other characteristics, including
history of cancer,
on quality of life in patients with CHC.
One hundred forty patients from clinics at three hospitals
in New York City completed a detailed epidemiologic interview
about demographic and lifestyle characteristics and the SF-36
measuring health-related quality of life.
The investigators compared results from their patients to
normative data using t-tests of differences between means.
They used multivariate analyses to determine other personal
and health-related factors associated with quality of life
outcomes.
Results
· Compared
to normative data, these patients had reduced quality of life,
particularly on physical functioning.
· The
summary Physical Component Score (PCS) was 45.4+/-10.6 and the
Mental Component Score (MCS) was 48.2+/-11.1, vs norms of 50+/-10.0;
p-values were <0.0001 and <0.05, respectively.
· In
multivariate analyses, the PCS was significantly lower among
those with cancer history, [greater than or equal to 2 other
chronic conditions], less education, low physical activity,
and higher alanine
aminotransferase (ALT) levels.
· Cancer
was more important for men, while other chronic conditions and
depression
were more important for women.
·
On the MCS, history of depression, low physical activity, alcohol
use, and female gender were independently associated
with poorer scores.
Conclusions
Several
health and lifestyle factors independently influence quality
of life in CHC patients. Different factors are important for
men and women.
07/06/05
Reference
S
H Olson and others. Cancer history and other personal
factors affect quality of life in patients with hepatitis
C. Health and Quality of Life Outcomes 3:39. June 16,
2005.
All
HCV Topics [
A to Z ]
2-log
Drop
Acute (Primary) HCV
Infection
Age
Alcohol / Smoking
/ Diabetes
ALT
Anemia
Children
Chronic HCV Infection
Cirrhosis
Cognitive Behavioral
Therapy
Complementary Therapies
(CAM)
Combination Treatment
Cryoglobulinemia
/ Cryoglobulin
Disease Progression
Decompensation
Developing Countries
Depression
Diabetes Mellitus
Dosing
Drug Abuse
Drug Pricing
Drug Related Adverse Events
Early Treatment Cessation
Early Virologic Response
Epidemiology / African
Americans
Epoetin Alpha
Early Viral Response
(EVR)
Eradication
Extrahepatic
Events
Experimental Treatment
Experimental
Therapy (procedure)
Fibrosis
Gender
Genetics
Genotype
1 and 4
Genotype
2 and 3
Genotype 5
and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines
HCV
Clearance
HCV Disease
Progression
HCV-Drug Related Adverse Events
HCV Recurrence
After Transplantation
Hearing
Hematological
Growth Factors
Hemodialysis
Hemoglobin
Hemophilia
Hepatic Decompensation
Hepatic Failure
Hematological Disorders
Hepatocellular
Carcinoma
Histology
Hormone
Therapies
hyaluronate
(HA)
Immunoglobulins
Immunosuppression
Induction Therapy
Injection Drug
Use
Infergen
Insulin Resistance
Interferon
Interferon
Resistance
Intron A
Kidney Disorders
Kidney Transplant
Liver Biopsy
Liver Enzymes
Liver
Issues
Living Donors
Liver Stiffness Measurement
(LSM)
Maintenance Therapy
Methadone
Miscellaneous
Mortality and Morbidity
Monotherapy Treatment
Mother
to Child Transmission of HCV
Natural
History
Neutropenia
Non-Alcoholic
Fatty Liver
Disease (NAFLD)
Non-Hepatic
Cancers
Non-Hodgkins
Lymphoma
Non-organ
Specific Autoantibodies
Nonresponders
/ Relapsers
Obesity
Occult
HBV Infection
Pathogenesis
Pegasys
PEG-Intron
Pegylated
Inferferon
Pharmacokinetics
Platelets
Pregnancy
Productivity
PIIINP/MMP-1,
prothrombin time (PT)
Quality
of Life
Quasispecies
Rapid
Virologic Response (RVR)
Recurrent
HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin
Dosing
Risk
Factors for HCC
Risk
Factors
Roferon
Seroconversion
Sex
(gender)
Sexual
Transmission
Skin
Reactions / Diseases
Sleeplessness
Steatosis
Steroids
Superinfection
Survival
Sustained Viral Response
Toxicities and Side Events
Transmission
Transplantation
Undetectable
HCV RNA
Viral
Eradication
Viral
Kinetics
Viral
Load
Weight-based
Dosing
Women
and Children
|
